HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

SIMPLE SUMMARY: Neoadjuvant chemotherapy strategy (NAC) is a standard of care for Human Epidermal Growth Factor Receptor-2 (HER2)-positive early breast cancer but there is no proven beneficial evidence in terms of survival compared to the adjuvant chemotherapy strategy. Our retrospective study found...

Descripción completa

Detalles Bibliográficos
Autores principales: Laas, Enora, Bresset, Arnaud, Féron, Jean-Guillaume, Le Gal, Claire, Darrigues, Lauren, Coussy, Florence, Grandal, Beatriz, Laot, Lucie, Pierga, Jean-Yves, Reyal, Fabien, Hamy, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864202/
https://www.ncbi.nlm.nih.gov/pubmed/33498405
http://dx.doi.org/10.3390/cancers13030370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864202/
https://www.ncbi.nlm.nih.gov/pubmed/33498405
http://dx.doi.org/10.3390/cancers13030370

Ejemplares similares